10x Genomics(TXG) Prnewswire·2025-01-12 17:00Company Performance - The company reported preliminary, unaudited FY 2024 revenue of approximately 165 million, representing 9% sequential growth [4] - Q4 2024 revenue of 610.8 million represented a 1% decrease from the prior year [10] - The company's cumulative instruments sold increased to over 7,000 by the end of 2024, including over 5,800 Chromium instruments, over 800 Visium instruments, and over 400 Xenium instruments [10] - Cash, cash equivalents, and marketable securities stood at approximately 24.4 million, showing 28% sequential growth but a 37% decrease compared to the prior year period [10] - Q4 2024 consumables revenue was approximately 7.1 million, showing 12% sequential growth and 35% growth over the prior year period [10] - FY 2024 instruments revenue was approximately 493.4 million, representing 3% growth over the prior year [10] - FY 2024 services revenue was approximately 10.9 million, while Spatial instruments revenue was approximately 97.7 million, while Spatial consumables revenue was approximately 35.2 million, while Spatial instruments revenue was approximately 372.3 million, while Spatial consumables revenue was approximately $121.1 million [10] Company Overview - The company is a life science technology firm focused on accelerating the mastery of biology and advancing human health [7] - Its integrated solutions include instruments, consumables, and software for single cell and spatial biology [7] - The company's products support breakthroughs in oncology, immunology, neuroscience, and other fields [7] Investor Relations - The company will participate in the 43rd Annual J P Morgan Healthcare Conference, with a live webcast available on January 13, 2025 [1] - The company discloses material non-public information through SEC filings, its website, press releases, conference calls, webcasts, and social media accounts [3]